Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Research shows lower dose drug strategy for severe COVID-19 patients both clinically and economically effective

Research shows lower dose drug strategy for severe COVID-19 patients both clinically and economically effective

News Releases Mar 23, 2022 3 minutes

News Release | 400 mg fixed dose tocilizumab holds out hope of extending the supply of life-saving medication and providing benefit to a larger number of severe COVID-19 patients.

Vancouver, B.C. - Scarcity of a drug central to the treatment of critically ill COVID-19 patients inspired British Columbia researchers to develop a novel dosing strategy that resulted in more people being treated with smaller doses of a life-saving drug.

Tocilizumab, an immunosuppressive drug originally developed to treat severe forms of inflammatory arthritis, became scarce in early 2021 after it was discovered to be an effective treatment for life-threatening cases of COVID-19. When given to COVID-19 patients, the drug inhibits Interleukin (IL)-6, one of the key cytokines in the COVID-19 cytokine storm syndrome that drives respiratory failure and death. 

To help alleviate shortages of the crucial drug, Vancouver Coastal Health Research Institute researcher Dr. Luke Chen proposed a unique strategy — providing patients with smaller, fixed doses of the drug, rather than the standard weight-based dose strategy.

Now, a new study published by Chen and his team in The Lancet Regional Health – Americas, found that a lower, fixed-dose tocilizumab strategy is both clinically and economically effective.

“To date, this study is the most comprehensive comparison of physiological parameters and clinical outcomes between fixed and weight-based dosing,” says Dr. Sophie Stukas, the study’s co-first author and associate research scientist at the University of British Columbia (UBC) Faculty of Medicine.

“It is also the first study to examine the cost effectiveness of these two strategies and is one of the few studies done in a critically ill population with a low overall mortality of less than 20 per cent,” adds Chen, program director, General Hematology Residency Program at Vancouver Coastal Health (VCH) and a clinical associate professor at the UBC Faculty of Medicine.

Dr. Luke Chen is a hematologist at Vancouver General Hospital. His research interests include Hemophagocytic lymphohistiocytosis (HLH) and other cytokine storm syndromes.

British Columbia began using tocilizumab with weight-based dosing (8 mg/kg to a maximum 800 mg) in January 2021 for critically ill patients with COVID-19. When supply shortages of tocilizumab hit, British Columbia adopted Chen’s strategy and switched to fixed dosing 400 mg IV for patients weighing more than 50 kg. The strategy surmised that the smaller dose would likely provide an equivalent short-term anti-inflammatory effect while allowing nearly twice as many patients to receive tocilizumab. 

Although randomized studies comparing tocilizumab doses require additional clinical consideration, this study adds to the body of observational data that demonstrates lower doses of tocilizumab — such as the 400 mg IV fixed dose strategy used in this study — increases the number of patients who will benefit from the medication in a climate of drug scarcity. The study findings have been supported by Dr. George Goshua at Yale University who also built a decision tree model to examine cost-effectiveness.
 
“Both doses demonstrated comparable reduction of inflammation and improvement on lung function,” says Chen. “In the context of ongoing drug shortages, a fixed-dose 400 mg of tocilizumab may be a practical, feasible and economical option.”  

The study was a collaboration between researchers at VCH, UBC and Yale University, with support from the Hsu & Taylor Family through VGH & UBC Hospital Foundation.

“COVID-19, while incredibly challenging, inspired a phenomenal collaborative spirit. This multi-institutional research was accelerated by a unified dedication to ease impacts of the global pandemic. Now we’re sharing results and contributing to the global knowledge of treatments for infectious diseases,” says Chen. “What’s more, these findings will create opportunities for further research and treatments for rare orphan diseases. The collaboration is a silver lining and one we hope to foster as we move forward.”

Researchers

Luke Chen

Related Articles

Heath care priority management post-COVID-19

COVID-19 linked to changes in the brain

Removing barriers to liver transplantation in COVID-19-postive patients

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Hematology Research Program

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2023 Recipients

Mar 21, 2023 award
Type
Stories

Ask an expert: Is my menstrual pain normal, or could I have endometriosis?

Mar 16, 2023 women, endometriosis, preventative
Type
Stories

Honing in on precision treatments for endometriosis

Mar 14, 2023 genetics, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy